Soligenix forms Psoriasis Medical Advisory Board; Phase 2a study starts December 2022

SOLIGENIX, INC.

Formed Medical Advisory Board (MAB) for SGX302 (synthetic hypericin) in mild-to-moderate psoriasis.
Phase 2a clinical study anticipated to begin in December 2022; FDA previously cleared IND and protocol.
MAB chaired by Neal Bhatia, MD (Therapeutics Clinical Research, San Diego).
Previous positive Phase 3 trial of HyBryte (same synthetic hypericin) in CTCL supports psoriasis program.
Psoriasis affects >7.5 million patients in the U.S.; MAB includes four board-certified dermatologists.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.